Management of Terlipressin-Unresponsive Hepatorenal Syndrome in Chronic Liver Disease

Initial Assessment and Treatment

The American Association for the Study of Liver Diseases recommends escalating the dose of terlipressin to 2 mg every 4-6 hours (maximum 12 mg/day) or switching to norepinephrine as an equally effective alternative, while continuing albumin and evaluating for liver transplantation, in patients who do not respond to initial terlipressin treatment 1, 2
Non-response to terlipressin is defined as <25% reduction in serum creatinine from baseline, and is associated with poor outcomes if mean arterial pressure (MAP) does not increase by ≥5 mmHg 1, 3
The International Ascites Club recommends verifying adequate albumin administration (1 g/kg day 1, then 20-40 g/day) in patients with hepatorenal syndrome 1, 2

The European Association for the Study of the Liver recommends increasing the terlipressin dose systematically when initial therapy fails, with a maximum dose of 12 mg/day 1, 3, 4, 5
Alternative dosing strategies include continuous infusion at 2 mg/day initially, which can be increased while potentially reducing ischemic side effects 1, 2, 6

The American College of Gastroenterology recommends switching to norepinephrine when terlipressin fails or is contraindicated, with a dosing regimen of 0.5 mg/hour (or 5 μg/min) titrated up to 3 mg/hour (or 10 μg/min) to achieve MAP increase >10 mmHg above baseline 1, 3, 7
Norepinephrine demonstrates non-inferiority to terlipressin with response rates of 39-70% 1, 7

Each 1 mg/dL reduction in creatinine (even partial response) reduces mortality risk by 27% 1, 2
Patients who achieve HRS reversal have significantly better survival than non-responders 1